William Blair analyst Matt Phipps has maintained their bullish stance on JANX stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matt Phipps has given his Buy rating due to a combination of factors tied to both current valuation and future clinical catalysts. He notes that JANX shares have sold off sharply from their 2025 highs, largely on negative sentiment around the December JANX007 update, and he sees upcoming data in 2026 or at a major medical meeting as a potential inflection point to rebuild confidence and unlock upside.
He also highlights that the ongoing dose optimization and expansion cohorts for JANX007 in multiple metastatic castration-resistant prostate cancer settings create several shots on goal. In addition, he frames Janux’s PSMA x CD3 approach within a broader competitive landscape, pointing to encouraging early data from a peer PSMA-targeted T-cell engager as validation of the therapeutic class and a supportive backdrop for Janux’s long-term prospects.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JANX in relation to earlier this year.